Incidence, persistence, and clearance of anogenital human papillomavirus among men who have sex with men in Taiwan: a community cohort study

Background Men who have sex with men (MSM) have an increased risk of human papillomavirus (HPV) infection. This study aimed to assess the incidence, persistence, and clearance of anogenital HPV infections among MSM and the correlates in a 3-year community cohort study. Methods From 2015 to 2019, MSM were recruited and followed up at 6, 12, 24, and 36 months in Taiwan. Questionnaires and anogenital swabs were collected at baseline and each follow-up visit. Thirty-seven HPV genotypes were tested and genotyped using the linear array HPV genotyping test. The incidence, persistence, and clearance rates of anogenital HPV infection and 95% confidence intervals (CIs) were estimated through Poisson regression. Correlates of the incidence and clearance rates were examined using a generalized estimating equations (GEE) model. Results A total of 201 MSM were retained in the cohort study with a median age of 27 years (interquartile range [IQR]: 24–32) at baseline. The incidence, persistence, and clearance rates of any anal HPV infection among MSM were 43.6 (95% CI: 33.7–55.6), 23.4 (17.7–30.2), and 58.3 (45.1–74.1) per 1,000 person months (pms), respectively. The incidence, persistence, and clearance rates of any penile HPV infection among MSM were 26.8 (20.1–34.9), 13.4 (8.0–20.9), and 51.5 (37.8–68.5) pms, respectively. MSM who did not consistently use a condom in receptive sex (adjusted odds ratio [AOR]: 2.06, 95% CIs: 1.14–3.72) were more likely to acquire any anal HPV infection. Age at recruitment (1.05, 1.01–1.09) was positively associated with any penile HPV incidence. MSM with over one sex partner in receptive anal sex (0.53, 0.30–0.94) were less likely to clear any anal HPV infection. MSM who were unemployed/students (0.55, 0.30–0.98) were less likely to clear any penile HPV infection. Conclusion High incidence and low clearance of anogenital HPV infection among MSM in the study serve as a reminder that this population needs to be targeted for HPV vaccination. It is essential for MSM to scale up HPV screening and adhere to safe sex.

[1]  R. Bruno,et al.  Substance use, socio‐demographic characteristics, and self‐rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study , 2023, The Medical journal of Australia.

[2]  H. D. de Melker,et al.  Approaches to Estimating Clearance Rates for Human Papillomavirus Groupings: A Systematic Review and Real Data Examples , 2022, Epidemiology.

[3]  C. Fairley,et al.  Global Pattern and Trends in Penile Cancer Incidence: Population-Based Study , 2022, JMIR public health and surveillance.

[4]  Miaomiao Xi,et al.  Natural History of Anal Papillomavirus Infection in HIV-Negative Men Who Have Sex With Men Based on a Markov Model: A 5-Year Prospective Cohort Study , 2022, Frontiers in Public Health.

[5]  H. Zou,et al.  Incidence, Persistence, and Clearance of Anal Human Papillomavirus among Men Who Have Sex with Men in China: An Observational Cohort Study , 2022, Pathogens.

[6]  Chung-Ying Lin,et al.  Predicting human papillomavirus vaccine uptake in men who have sex with men the influence of vaccine price and receiving an HPV diagnosis , 2022, BMC Public Health.

[7]  H. Jessen,et al.  Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. , 2021, The Lancet. Infectious diseases.

[8]  S. Garland,et al.  Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. , 2021, The Lancet. Infectious diseases.

[9]  S. Bruisten,et al.  Incidence and Clearance of Penile High-Risk Human Papillomavirus Infection and Their Determinants Among HIV-Negative Men Who Have Sex With Men , 2021, Sexually transmitted diseases.

[10]  J. Palefsky,et al.  Incidence, clearance, persistence and factors related with high-risk anal HPV persistence in South-East Asian MSM and transgender women. , 2020, AIDS.

[11]  S. Garland,et al.  The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. Delaugerre,et al.  Prevalence and incidence of HPV infection in men having sex with men enrolled in a PrEP study: A sub-study of the ANRS IPERGAY trial. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Ferlay,et al.  Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. , 2019, The Lancet. Global health.

[14]  C. J. Alberts,et al.  Estimating incidence rates of grouped HPV types: A systematic review and comparison of the impact of different epidemiological assumptions , 2019, Papillomavirus research.

[15]  S. J. Henley,et al.  Human Papillomavirus–Attributable Cancers — United States, 2012–2016 , 2019, MMWR. Morbidity and mortality weekly report.

[16]  J. Routy,et al.  Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.

[17]  C. Strong,et al.  Sexual network and detection of anogenital human papillomavirus in a community cohort of men who have sex with men in Taiwan , 2019, PloS one.

[18]  N. Xia,et al.  Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study , 2019, International journal of cancer.

[19]  C. Strong,et al.  Prevalence and risk factors of anogenital human papillomavirus infection in a community sample of men who have sex with men in Taiwan: baseline findings from a cohort study , 2019, Sexually Transmitted Infections.

[20]  R. Kohn,et al.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016. , 2018, The Journal of infectious diseases.

[21]  E. Unger,et al.  Seroprevalence of human papillomavirus 6/11/16/18 among self-identified gay/bisexual men who have sex with men, men who have sex with women, and females, United States, 2003-2010. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Evans,et al.  Gender neutral vaccination against HPV , 2018, British Medical Journal.

[23]  A. Boyd,et al.  Incidence and Clearance of Anal High-risk Human Papillomavirus Infections and Their Determinants Over 5 Years Among Human Immunodeficiency Virus-negative Men Who Have Sex With Men. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Gang Liu,et al.  A cohort study , 2018 .

[25]  J. Palefsky,et al.  Prevalence, Incidence, and Clearance of Anal High-Risk Human Papillomavirus Infection Among HIV-Infected Men in the SUN Study , 2018, The Journal of infectious diseases.

[26]  J. Vecchiet,et al.  Prevalence of anal, oral, penile and urethral Human Papillomavirus in HIV infected and HIV uninfected men who have sex with men , 2018, Journal of medical virology.

[27]  G. Lyratzopoulos,et al.  Associations Between Sexual Orientation and Overall and Site-Specific Diagnosis of Cancer: Evidence From Two National Patient Surveys in England , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Mainous,et al.  Prevalence and Risk of Penile Human Papillomavirus Infection: Evidence From The National Health and Nutrition Examination Survey 2013–2014 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Colafigli,et al.  Anal human papillomavirus in HIV-uninfected men who have sex with men: incidence and clearance rates, duration of infection, and risk factors. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  A. Hartmann,et al.  Shift in prevalence of HPV types in cervical cytology specimens in the era of HPV vaccination. , 2016, Oncology letters.

[31]  A. Giuliano,et al.  Incidence, Duration, Persistence, and Factors Associated With High-risk Anal Human Papillomavirus Persistence Among HIV-negative Men Who Have Sex With Men: A Multinational Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  S. Altekruse,et al.  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. , 2015, Journal of the National Cancer Institute.

[33]  A. Giuliano,et al.  Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study , 2011, The Lancet.

[34]  E. Unger,et al.  Type‐specific reproducibility of the Roche Linear Array HPV Genotyping Test , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[35]  J. Berzofsky,et al.  Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. , 2006, Cancer research.

[36]  Søren Højsgaard,et al.  The R Package geepack for Generalized Estimating Equations , 2005 .

[37]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[38]  N. Xia,et al.  Sex differences in the incidence and clearance of anogenital human papillomavirus infection in Liuzhou, China: an observational cohort study. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  S. Syrjänen,et al.  [HPV and cancer]. , 2015, Duodecim; laaketieteellinen aikakauskirja.

[40]  G. Plazzi,et al.  A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. , 2011, Sleep medicine.